In vitro interaction of currently used azoles with terbinafine against Madurella mycetomatis.
作者信息
Ahmed Sarah Abdalla, Kloezen Wendy, Fahal Ahmed H, de Hoog G Sybren, van de Sande Wendy W J
机构信息
Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan CBS-KNAW Fungal Biodiversity Centre, Utrecht, The Netherlands Institute for Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands
Erasmus MC, Department of Medical Microbiology and Infectious Diseases, Rotterdam, The Netherlands.
出版信息
Antimicrob Agents Chemother. 2015 Feb;59(2):1373-4. doi: 10.1128/AAC.04487-14. Epub 2014 Dec 8.
Abstract
摘要
相似文献
1
In vitro interaction of currently used azoles with terbinafine against Madurella mycetomatis.
Antimicrob Agents Chemother. 2015 Feb;59(2):1373-4. doi: 10.1128/AAC.04487-14. Epub 2014 Dec 8.
2
In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine.
Antimicrob Agents Chemother. 2011 Apr;55(4):1771-3. doi: 10.1128/AAC.01045-10. Epub 2011 Jan 24.
3
In vitro antifungal activity of isavuconazole against Madurella mycetomatis.
Antimicrob Agents Chemother. 2012 Nov;56(11):6054-6. doi: 10.1128/AAC.01170-12. Epub 2012 Sep 10.
4
Madurella mycetomatis is highly susceptible to ravuconazole.
PLoS Negl Trop Dis. 2014 Jun 19;8(6):e2942. doi: 10.1371/journal.pntd.0002942. eCollection 2014 Jun.
5
Azoles, allylamines and drug metabolism.
Br J Dermatol. 1992 Feb;126 Suppl 39:14-8. doi: 10.1111/j.1365-2133.1992.tb00003.x.
6
Amphotericin B and terbinafine but not the azoles prolong survival in Galleria mellonella larvae infected with Madurella mycetomatis.
Med Mycol. 2018 Jun 1;56(4):469-478. doi: 10.1093/mmy/myx064.
7
Combining two antifungal agents does not enhance survival of Galleria mellonella larvae infected with Madurella mycetomatis.
Trop Med Int Health. 2017 Jun;22(6):696-702. doi: 10.1111/tmi.12871. Epub 2017 May 2.
8
Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole.
Microbes Infect. 2007 Jul;9(9):1114-23. doi: 10.1016/j.micinf.2007.05.015. Epub 2007 May 18.
9
In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay.
Antimicrob Agents Chemother. 2004 Jul;48(7):2742-6. doi: 10.1128/AAC.48.7.2742-2746.2004.
10
Development and Validation of an Resazurin-Based Susceptibility Assay against .
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01338-20.
引用本文的文献
1
Eumycetoma causative agents: A systematic review to inform the World Health Organization priority list of fungal pathogens.
Med Mycol. 2024 Jun 27;62(6). doi: 10.1093/mmy/myae044.
2
The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo.
Med Mycol. 2023 Nov 6;61(11). doi: 10.1093/mmy/myad118.
3
An update on the development of novel antifungal agents for eumycetoma.
Front Pharmacol. 2023 May 18;14:1165273. doi: 10.3389/fphar.2023.1165273. eCollection 2023.
4
Epidemiological cut-off values for itraconazole and ravuconazole for Madurella mycetomatis, the most common causative agent of mycetoma.
Mycoses. 2022 Dec;65(12):1170-1178. doi: 10.1111/myc.13509. Epub 2022 Aug 25.
5
Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella.
Med Mycol. 2022 Feb 2;60(2). doi: 10.1093/mmy/myac003.
6
In vitro susceptibility testing for black grain eumycetoma causative agents.
Trans R Soc Trop Med Hyg. 2021 Apr 14;115(4):343-354. doi: 10.1093/trstmh/traa184.
7
Madurella mycetomatis causing eumycetoma medical treatment: The challenges and prospects.
PLoS Negl Trop Dis. 2020 Aug 27;14(8):e0008307. doi: 10.1371/journal.pntd.0008307. eCollection 2020 Aug.
8
Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.
J Antimicrob Chemother. 2020 Apr 1;75(4):936-941. doi: 10.1093/jac/dkz529.
本文引用的文献
1
Susceptibility of clinically important dermatophytes against statins and different statin-antifungal combinations.
Med Mycol. 2014 Feb;52(2):140-8. doi: 10.3109/13693786.2013.828160.
2
In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine.
Antimicrob Agents Chemother. 2011 Apr;55(4):1771-3. doi: 10.1128/AAC.01045-10. Epub 2011 Jan 24.
3
The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis.
Trans R Soc Trop Med Hyg. 2011 Mar;105(3):127-32. doi: 10.1016/j.trstmh.2010.11.008. Epub 2011 Jan 17.
4
Clinical efficacy and safety of oral terbinafine in fungal mycetoma.
Int J Dermatol. 2006 Feb;45(2):154-7. doi: 10.1111/j.1365-4632.2004.02392.x.
5
Mycetoma caused by Madurella mycetomatis: a neglected infectious burden.
Lancet Infect Dis. 2004 Sep;4(9):566-74. doi: 10.1016/S1473-3099(04)01131-4.
6
In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay.
Antimicrob Agents Chemother. 2004 Jul;48(7):2742-6. doi: 10.1128/AAC.48.7.2742-2746.2004.
7
Mycetoma.
Br J Dermatol. 1994 Nov;131(5):722-3.
8
Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii.
Trans R Soc Trop Med Hyg. 1984;78(3):376-9. doi: 10.1016/0035-9203(84)90126-3.
Zotero 插件